Pharmaceuticals R&D Event | June 28, 2023

Bayer has been researching and developing innovative medications and new therapeutic approaches that help make a difference to people’s lives for more than a century. We are determined to drive breakthrough innovations for patients in diseases of high unmet medical need.

At this event, Stefan Oelrich, President of the Pharmaceuticals Division and Member of the Board of Management of Bayer AG, along with Christian Rommel, Global Head of R&D, Bayer Pharmaceuticals and other top scientists from the Pharmaceuticals division provided a strategic update on our R&D activities and latest insights into our R&D progress and ambitions. In addition, Seth Ettenberg, President and Chief Executive Officer of BlueRock Therapeutics, and R. Jude Samulski, President, Chief Scientific Officer and Co-Founder of AskBio, gave insights into our activities in the field of cell and gene therapies. Aleksandra Rizo, President and Chief Executive Officer of Vividion Therapeutics talked about the possibilities in drug discovery using a chemoproteomics platform.